SARS-CoV-2 vaccination reduces the risk of thrombotic complications in severe COVID-19

Abstract

Objectives

The aim of this study was to evaluate the association between SARS-CoV-2 vaccination and the occurrence of thrombotic complications in patients admitted to intensive care for severe COVID-19 pneumonia.

Design

Observational, descriptive, prospective, multicentre study.

Setting

Intensive care units of five university hospitals.

Patients

A total of 255 patients admitted to the intensive care unit (ICU) with SARS-CoV-2 pneumonia, confirmed by RT-PCR in throat swab or tracheal aspirate, starting the date the first vaccinated patient against SARS-CoV-2 was admitted in one of the participating ICUs, were included in the analysis.

Main variables of interest

Vaccination status against SARS-CoV-2 and thrombotic events.

Results

18.8% of patients had received some form of vaccination. Thrombotic events occurred in 21.2% of patients. Lack of vaccination was associated with thrombotic events (OR 5.024; 95% CI: 1.104−23.123; p = 0.0037) and death (OR 5.161; 95% CI: 1.075–24.787; p = 0.04). ICU mortality was not associated with the occurrence of thrombotic complications.

Conclusions

In this series of patients, vaccination against SARS-CoV-2 reduced the risk of thrombotic events and mortality in patients with severe COVID-19 admitted to the ICU. Thrombotic complications did not alter ICU mortality.